Nutriband FY27 Q1 net loss narrows to $1.24 million; revenue falls to $433,399

• Nutriband posted a net loss of $1.24 million, or $(0.10) a share, for the quarter ended April 30, 2026, narrowing from a loss of $1.39 million.
• Revenue fell to $433,399 from $667,432, reflecting lower Pocono Pharmaceuticals sales; 4P Therapeutics generated no revenue.
• Selling, general and administrative expenses rose to $1.2 million from $982,052, while research and development spending dropped to $247,261 from $683,426.
• Cash and cash equivalents totaled $4.01 million at April 30, 2026, down from $4.57 million at Jan. 31, 2026, as operating cash outflow was $563,104.
• On the product side, Nutriband highlighted its AVERSA Fentanyl development work with Kindeva under a revised exclusive partnership framework tied to shared costs and milestone payments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-067840), on June 11, 2026, and is solely responsible for the information contained therein.